Policosanol in Coronary Artery Disease

Effects of policosanol in patients with coronary artery disease.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000470

Enrollment

150

Registered

2026-02-18

Start date

2026-03-30

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Group 1, Policosanol (20 mg/day) (Experimental): 1 policosanol tablet (20 mg) + 1 placebo tablet + 1 aspi-rin tablet (81 mg), by oral route, with breakfast for 12 months. Group 2, Policosanol (40 mg/d

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of both sexes = 18 years with ischemic heart disease, unstable angina or acute coronary syndrome (myocardial infarction without or with ST segment elevation).

Exclusion criteria

Exclusion criteria: 1. Patients under 18 years of age with ischemic heart disease, arrhythmias with hemodynam-ic compromise, or heart failure of valvular origin. 2. Patients with stents. 3. Patients with electrocardiographic images of chronic myocardial ischemia. 4. Patients with a prior history of stroke (ischemic or hemorrhagic), or peripheral arterial dis-ease diagnosed as intermittent claudication. 5. Diagnosed neoplasms. 6. Use of medications that could affect platelet aggregation (clopidogrel) and/or the lipid pro-file (statins). A7. llergy to any component of the study medication or any other special medical condition that, in the physician's judgment, may endanger the patient's health and life during the study, taking into account the expected effects of the treatment and the patient's clinical condition at that time.

Design outcomes

Primary

Measure	Time frame
1. Platelet aggregation compared (values of arachidonic acid (mmol/L), collagen (ug/mL), ADP (mmol/L). Measurement time: At baseline, and at 3, 6, 9 and 12 months of treatment. 2. Values of LDL-C , Total cholesterol, and HDL-C (values expressed in mmol/L). Measurement time: At baseline and at 3, 6, 9 and 12 months of treatment. Measurement time: At baseline, and at 3, 6, 9 and 12 months of treatment.	—

Measure

Time frame

1. Platelet aggregation compared (values of arachidonic acid (mmol/L), collagen (ug/mL), ADP (mmol/L). Measurement time: At baseline, and at 3, 6, 9 and 12 months of treatment. 2. Values of LDL-C , Total cholesterol, and HDL-C (values expressed in mmol/L). Measurement time: At baseline and at 3, 6, 9 and 12 months of treatment. Measurement time: At baseline, and at 3, 6, 9 and 12 months of treatment.

—

Secondary

Measure	Time frame
Carotid intima-media thickness (value in mm measured using a carotid ultrasound). Measurement time: At baseline, and at 6 and 12 months of treatment.	—

Countries

Cuba

Contacts

Public ContactLeando Martinez Navarro

10 de octubre Clinical Sugical Teaching Hospital

leandro.martinez@infomed.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 25, 2026